查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1867047

动物模型市场：2025-2032年全球预测（按动物类型、模型类型、应用和最终用户划分）

Animal Model Market by Animal Type, Model Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，动物模型市场将成长至 59.8 亿美元，复合年增长率为 8.28%。

关键市场统计数据
基准年 2024 31.6亿美元
预计年份：2025年 34.2亿美元
预测年份 2032 59.8亿美元
复合年增长率 (%) 8.28%

全面介绍科学进步、伦理要求和监管期望如何融合，从而重新定义临床前动物模型策略。

现代动物模型领域正处于快速科学创新、严格的伦理要求和不断发展的监管三者交汇的境地。临床前研究人员和机构领导者必须应对日益复杂的环境，基因编辑技术的进步、饲养和模型表征的改进以及不断提高的可重复性标准共同影响决策。随着研究机构、药物研发人员和服务供应商不断调整，对模型选择、营运韧性和合规性方面的明确需求，对维持转化研究的持续发展构成了核心挑战。

在此背景下，相关人员日益强调检验的疾病模型和基因工程系统对于提高疾病相关性的重要性，同时也要应对外部压力，改善动物使用方式并提升动物福利。这种动态变化要求我们对模型的能力和限制有深入的了解，并在适当情况下采用替代技术整合策略。因此，如何使科学目标与营运结构、供应商生态系统和监管要求相协调，已成为计划成功和伦理管治的关键因素。

基因编辑技术、以福利为中心的管治和数位融合如何改变模型开发、检验方法和合作研究框架

一场变革浪潮正在重塑生物医学研究中动物模型的发展、检验和应用方式。精准基因编辑技术的进步，特别是基于CRISPR的方法，正在加速建立高度精确的基因修饰模型，这些模型能够更真实地模拟人类疾病的生物学过程。这正在改变模型选择和实验设计的标准。同时，表型表征和体内成像技术的改进增强了纵向研究的能力，并减少了达到可靠终点所需的动物数量，从而影响了资源分配和研究週期。

同时，伦理和监管环境对实验实践的影响日益增强。各机构和赞助商正在加强管治结构，以符合国际3R原则，从而加强对动物福利的监管，并要求对动物使用进行更充分的论证。为此，服务提供者和内部团队正在加大对动物福利设施、丰富化计画和员工培训的投入，以满足伦理要求和科学品质目标。同时，数位转型和数据整合（包括实验室资讯管理系统、标准化元资料实践和机器学习驱动的分析）也在不断发展，提高了实验的可重复性，并加快了不同研究之间的比较。这些变化共同推动实验模式向专业服务提供者的协作网络、集中式模型库和能够提供更可靠转化研究结果的多学科团队转变。

2025年美国贸易政策演变对临床前供应链、采购韧性与跨境合作准备的影响

美国预计在2025年将推出的政策干预措施和关税调整，将为临床前供应链和跨国合作带来新的挑战。影响特殊生物材料、客製化试剂和设备进出口的贸易措施，可能会影响采购前置作业时间和供应商选择。因此，依赖国际供应商提供基因改造品系、种畜、专用耗材等产品的机构，可能需要重新评估其筹资策略，以减轻进口合规性审查加强和潜在成本重新分配对其营运的影响。

在实践中，这些贸易趋势正促使企业更加重视供应商多元化、关键产能回流以及在可行的情况下推动供应链区域化。各组织正在推动加强合约保障、完善库存计划以及对多家供应商进行认证，以确保研究的连续性并降低政策引发的中断风险​​。此外，关税对话正在促进行业相关人员和监管机构之间的讨论，以协调材料转移、检疫和文件标准，并最大限度地减少行政摩擦。最后，对调查计画而言，需要将贸易政策风险纳入计划时程和采购管治，以确保在跨境法规不断变化的情况下，科学目标仍能有效实现。

可操作的細項分析揭示了物种选择、模型建构、应用领域和最终用户画像如何产生不同的操作和科学优先事项。

細項分析揭示了动物物种、模型建构、应用领域和最终用户如何塑造临床前生态系统中多样化的需求和策略重点。物种维度区分了非囓齿类动物和囓齿类动物，其中非囓齿类动物包括犬、非人灵长类动物和兔子等物种，而囓齿类动物则包括仓鼠、豚鼠、小鼠和大鼠。这种生物多样性导致了法律规范、饲养要求和转化应用的差异。因此，物种选择决策越来越需要基于生理相关性和操作因素（例如繁殖週期、饲养空间和福利通讯协定）之间的平衡。

模型类型的划分进一步增加了复杂性：疾病模型、基因工程模型、药理学模型和手术模型各自服务于不同的实验目的。在基因工程方法中，CRISPR模型、基因敲入模型、基因敲除模型和基因转殖模型等细分模型在技术架构和适用性方面存在差异，可用于标靶检验、机制研究和治疗试验。这些差异不仅影响实验设计，也影响检验途径和可重复性预期，因此各机构需要针对每类模型製定专门的标准作业规程（SOP）和表征流程。

应用领域涵盖ADME/PK研究、疾病研究、药物发现与开发以及毒性评估，每个领域都有其独特的可重复性要求、终点选择和资料来源需求。例如，ADME和药物动力学研究优先考虑受控的生理条件和精确的采样，而疾病研究可能需要复杂的表型分析和纵向结果测量。因此，对检测平台、成像技术和生物分析能力的营运投资通常与组织的主要应用领域相符。

最终用户涵盖学术和研究机构、合约研究组织、医院和诊断实验室，以及製药和生物技术公司，每个用户群体都有不同的采购行为、监管责任和时间表。学术实验室往往优先考虑探索性的灵活性和开放科学实践，而合约研究组织则专注于满足申办者要求的可扩展、检验的工作流程。临床实验室和医疗系统将临床前研究结果整合到转化研究路径和诊断开发中，而产业伙伴则需要强而有力的模型论证来支持监管申报。认识到这些基于细分市场的差异，有助于相关人员根据关键最终用户群体的具体需求，调整模型选择、供应商伙伴关係和管治框架。

区域分析重点在于美洲、欧洲、中东和非洲以及亚太地区对采购、合规和合作研究策略的影响。

区域趋势正在影响关键地区动物模型来源、监管合规和合作研究策略的组织方式。美洲仍然是治疗创新和合约研究活动的中心，密集的学术机构和商业赞助商网络推动了对特征明确模型和专业服务的需求。这种能力的集中支持了强大的转化项目，同时也加剧了对人才、基础设施和实验室空间的竞争，并促进了策略联盟和资源共用模式的形成，从而优化了研究效率。

欧洲、中东和非洲地区拥有多元化的法规结构和伦理标准，这些都对模型开发和跨境交换产生影响。该地区许多司法管辖区都强调严格的动物福利标准和统一的监管，从而影响供应商认证实践和研究设计要求。此外，区域合作联盟和官民合作关係在汇集资源进行大规模临床前倡议以及推广标准化模型检验标准方面发挥重要作用。

亚太地区正迅速崛起为服务提供和模式创新领域的活力中心，这主要得益于基因编辑能力、育种基础设施和合约研究能力的快速投资。各国监管方式的差异为区域专业化创造了机会，而不断增长的本土科学专长则促进了本土模式开发和转化研究项目的发展。这些区域趋势凸显了针对各区域独特风险和收益量身定制的筹资策略、合规蓝图和伙伴关係模式的重要性。

透过专业知识、数据整合和监管服务交付，推动竞争优势的策略性企业行动和伙伴关係模式

动物模型生态系统中主要企业的行动体现了以专业化、垂直整合和协作服务交付为核心的策略重点。领先的供应商正投资于高保真基因操作技术和强大的育种项目，以提供差异化的模型产品组合。同时，许多服务公司正在拓展其分析和生物资讯服务，以在动物生产之外创造更多价值。这种将技术服务与先进数据解读相结合的趋势，旨在弥合转化医学鸿沟，并为申办方提供来自临床前计画的更具可操作性的见解。

另一个重要的发展方向是透过伙伴关係与联盟整合各项能力。这使得企业能够结合营运优势，例如动物饲养管理、再生医学专业知识和生物成像技术，从而提供全面的服务。同时，一些供应商正在推行模组化外包模式，允许赞助公司在无需全面整合的情况下获得特定能力。在这些策略中，对监管资讯、品管系统和动物福利认证的投资十分普遍，因为客户越来越要求整个供应链具备可验证的标准和可追溯性。这些公司层面的选择将影响整个产业的竞争定位、客户维繫以及不断变化的服务水准预期。

为研究领导者提供切实可行的、优先排序的策略建议，以加速转化成果的取得，同时提高模型可信度、加强供应链并改善福利合规性。

为了掌握当前机会并降低新兴风险，产业领导者应积极整合科学研究投资、增强供应链韧性并管治。首先，引入先进的基因修饰模型技术（特别是CRISPR平台和全面的表型分析流程）将有助于提高标靶检验，并降低下游转化研究的不确定性。同时，各机构应制定模型表征标准，并建立跨职能审查流程，以确保研究结果的可重复性和科学依据。

其次，供应链策略必须不断演进，以降低贸易政策变化和供应中断带来的风险。这包括供应商关係多元化、对区域供应商合格，以及为关键任务材料建立紧急库存。此外，投资本地养殖能力和建立区域伙伴关係可以缩短前置作业时间，并在商业不确定时期提供营运缓衝。第三，企业应透过整合强化监控技术、独立审核和员工发展计划，加强其福利和合规管治，以符合不断变化的道德期望和监管要求。

最后，领导者应充分利用资料科学和数位平台来提高实验效率。标准化元资料收集、实施可互通的实验室系统以及部署机器学习进行终点预测，将提高实验的可重复性，并支援更快的决策週期。这些措施将增强科学信誉、营运稳定性以及相关人员的信任，为各机构在应对政策和伦理要求的同时保持转化研究动力奠定基础。

结合专家访谈、系统性文献综述和迭代检验的稳健的多源调查方法，确保了研究结果的有效性和可操作性。

本分析的调查方法采用分层式策略，将初步的质性见解与结构化的二次检验结合。初步资讯包括咨询临床前研究、兽医学和监管事务领域的专家，以捕捉细微的营运实际情况和新兴的科学趋势。此外，也透过系统性地回顾同侪审查文献、技术指导文件和公认标准，来阐释技术进步和动物福利实践的背景。

透过资料三角验证，将专家意见与已发布的技术调查方法透明公开，清楚记录了纳入标准、模型分类定义以及技术论点的依据。整个过程中都强调了伦理考量，并在专家访谈中尊重了资料隐私和职业保密。这种多来源、迭代式的方法有助于对行业趋势进行合理的解读，并为寻求营运指导和科学依据的决策者提供量身定制的见解。

总之，强调整合科学严谨性、伦理管治和供应链韧性的整体观点将有助于转化研究的持续成功。

总之，动物模型领域正经历专业化程度提高、伦理课责加强和运作模式调整的阶段。基因编辑和表型表征等科学进步正在提升模型的转化准确性，而监管机构和相关人员也不断提高对动物福利和可重复性的要求。这些并行发展的趋势要求各机构谨慎选择模型，增强供应链的灵活性，并投资于能够支援可靠转化结果的资料管治基础设施。

未来的成功取决于能否将技术能力、负责任的管理和切实可行的营运规划融会贯通。那些积极将科研议程与强有力的采购惯例实践和透明的福利管治相结合的机构，将更有能力提供高品质的临床前证据，并能灵活应对政策和市场的变化。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • CRISPR/Cas9基因编辑动物模型在罕见疾病研究和药物研发的快速应用
  • 越来越多地采用人源化小鼠模型来评估肿瘤免疫疗法的疗效和安全性
  • 将人工智慧驱动的影像分析和行为追踪技术整合到临床前动物模型表型分析工作流程中
  • 加大对大型动物模型（例如猪和非人灵长类动物）在异种移植研究中的投入
  • 晶片器官和3D生物列印组织平台作为传统动物试验的替代方案的出现
  • 监管压力推动体外和计算模型的发展，以减少对动物测试的依赖

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：以动物类型分類的动物模型市场

  • 不囓齿类动物
    • 狗
    • 非人灵长类动物
    • 兔子
  • 囓齿动物
    • 仓鼠和天竺鼠
    • 老鼠
    • 鼠

第九章：依模型类型分類的动物模型市场

  • 疾病模型
  • 基因工程模型
    • CRISPR模型
    • 敲入式模型
    • 淘汰赛模特儿
    • 基因改造模型
  • 药理学模型
  • 手术模型

第十章：按应用分類的动物模型市场

  • ADME和药物动力学研究
  • 疾病监测
  • 药物发现与开发
  • 毒性评价

第十一章 按最终用户分類的动物模型市场

  • 学术和研究机构
  • CRO（合约研究组织）
  • 医院和诊断实验室
  • 製药和生物技术公司

第十二章：各地区动物模型市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：依组别分類的动物模型市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国动物模型市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Charles River Laboratories International, Inc.
    • Envigo RMS, Inc.
    • The Jackson Laboratory
    • Taconic Biosciences, Inc.
    • Laboratory Corporation of America Holdings
    • Wuxi AppTec Co., Ltd.
    • Evotec AG
    • Crown Bioscience, Inc.
    • Janvier Labs SAS
    • GemPharmatech Co., Ltd.
Product Code: MRR-5D693B46BD18

The Animal Model Market is projected to grow by USD 5.98 billion at a CAGR of 8.28% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.16 billion
Estimated Year [2025] USD 3.42 billion
Forecast Year [2032] USD 5.98 billion
CAGR (%) 8.28%

A comprehensive introduction outlining how scientific progress, ethical imperatives, and regulatory expectations converge to redefine preclinical animal model strategies

The contemporary animal model landscape sits at the intersection of rapid scientific innovation, stringent ethical expectations, and evolving regulatory oversight. Preclinical investigators and organizational leaders must navigate an increasingly complex environment where advances in gene editing, improvements in husbandry and model characterization, and heightened reproducibility standards collectively influence decision-making. As research institutions, pharmaceutical developers, and service providers adapt, the demand for clarity around model selection, operational resilience, and compliance has become central to sustaining translational pipelines.

Across this environment, stakeholders are placing greater emphasis on validated disease models and genetically engineered systems to increase translational relevance while simultaneously responding to external pressures to refine animal use and enhance welfare. This dynamic requires a nuanced understanding of model capabilities and limitations, as well as strategies for integrating alternative technologies where appropriate. Consequently, the ability to align scientific objectives with operational structures, vendor ecosystems, and regulatory expectations is now a critical determinant of project success and ethical stewardship.

How gene editing, welfare-driven governance, and digital integration are jointly transforming model development, validation practices, and collaborative research frameworks

Significant transformative shifts are reshaping how animal models are developed, validated, and deployed across biomedical research. Advances in precision gene editing, particularly CRISPR-based approaches, are accelerating the creation of highly specific genetically engineered models that better recapitulate human disease biology, thereby changing the calculus for model selection and experimental design. At the same time, improvements in phenotype characterization and in vivo imaging are enhancing longitudinal study capabilities and reducing the number of animals required for robust endpoints, which in turn affects resource allocation and study timelines.

Concurrently, ethical and regulatory landscapes are exerting stronger influence over experimental practice. Institutions and sponsors are strengthening governance frameworks to align with international 3Rs principles, resulting in more rigorous welfare monitoring and justification for animal use. In response, service providers and internal teams are increasingly investing in welfare-positive housing, enrichment programs, and staff training to meet both ethical expectations and scientific quality goals. In parallel, digital transformation and data integration-encompassing laboratory information management systems, standardized metadata practices, and machine learning-enabled analytics-are improving reproducibility and enabling more rapid cross-study comparisons. These combined shifts are driving a migration toward collaborative networks of specialized providers, centralized model repositories, and multidisciplinary teams that can deliver higher-confidence translational outputs.

Implications of evolving US trade measures for preclinical supply chains, procurement resilience, and cross-border collaboration preparedness in 2025

Policy interventions and tariff adjustments in the United States projected for 2025 are introducing new considerations for preclinical supply chains and cross-border collaborations. Trade measures that affect the import and export of specialized biological materials, custom reagents, and equipment can influence procurement lead times and vendor selection decisions. As a result, organizations that rely on international suppliers for genetically engineered lines, breeding stock, or specialized consumables may need to reassess sourcing strategies to mitigate the operational impact of elevated import compliance scrutiny and potential cost reallocation.

In practical terms, these trade dynamics are prompting greater attention to supplier diversification, onshoring of critical production capabilities, and regionalization of supply chains where feasible. Organizations are emphasizing contractual protections, enhanced inventory planning, and multi-supplier qualification to ensure continuity of studies and reduce exposure to policy-driven disruptions. Moreover, the tariffs dialogue is catalyzing conversations between industry stakeholders and regulatory authorities about harmonizing standards for material transfer, quarantine, and documentation to minimize administrative friction. Ultimately, the implication for research programs is a need to integrate trade policy risk into project timelines and procurement governance so that scientific objectives remain resilient in the face of shifting cross-border rules.

Actionable segmentation intelligence revealing how species selection, model construction, application focus, and end-user profiles create differentiated operational and scientific priorities

Segmentation insights reveal how distinct animal types, model constructs, application areas, and end users shape heterogeneous demands and strategic priorities across the preclinical ecosystem. The animal type dimension differentiates Nonrodents and Rodents, where Nonrodents encompass species such as Dogs, Nonhuman Primates, and Rabbits, and Rodents include Hamsters & Guinea Pigs, Mice, and Rats; this biological diversity drives variation in regulatory oversight, housing requirements, and translational applicability. Therefore, decisions about species selection are increasingly informed by the balance between physiological relevance and operational considerations such as breeding cycles, housing footprint, and welfare protocols.

Model type granularity further layers complexity: Disease Models, Genetically Engineered Models, Pharmacological Models, and Surgical Models each serve distinct experimental purposes. Within genetically engineered approaches, subdivisions such as CRISPR Models, Knock-In Models, Knockout Models, and Transgenic Models differ in their technical construction and applicability for target validation, mechanistic studies, and therapeutic testing. These differences influence not only experimental design but also validation pathways and reproducibility expectations, leading organizations to develop tailored standard operating procedures and characterization pipelines for each model class.

Applications span ADME & PK Studies, Disease Research, Drug Discovery & Development, and Toxicology Assessment, and each application imposes unique fidelity requirements, endpoint selection, and data provenance needs. For instance, ADME and pharmacokinetic investigations prioritize controlled physiology and precise sampling, whereas disease research may require complex phenotyping and longitudinal outcome measures. As a result, operational investments in assay platforms, imaging modalities, and bioanalytical capacity are frequently aligned to the dominant application portfolio of an organization.

End users range from Academic & Research Institutes to Contract Research Organizations, Hospitals & Diagnostic Laboratories, and Pharmaceutical & Biotechnology Companies, each bringing different procurement behaviors, regulatory responsibilities, and timelines. Academic labs often prioritize exploratory flexibility and open science practices, while contract research organizations focus on scalable, validated workflows that meet sponsor requirements. Clinical laboratories and health systems integrate preclinical insights into translational pathways and diagnostic development, and industry partners require robust model justification to support regulatory submissions. Recognizing these segmentation-driven differences enables stakeholders to align model selection, vendor partnerships, and governance frameworks with the specific needs of their primary end-user constituencies.

Regional analysis highlighting how the Americas, Europe Middle East & Africa, and Asia-Pacific each influence sourcing, compliance, and collaborative research strategies

Regional dynamics are shaping how organizations approach animal model sourcing, regulatory compliance, and collaboration strategies across key geographies. The Americas continue to be a hub for therapeutic innovation and contract research activity, with dense networks of academic institutions and commercial sponsors that drive demand for characterized models and specialized services. This concentration of capability supports robust translational programs, yet it also elevates competition for talent, infrastructure, and laboratory space, encouraging strategic alliances and shared-resource models to optimize throughput.

Europe, Middle East & Africa present a mosaic of regulatory frameworks and ethical norms that influence model development and cross-border exchanges. Many jurisdictions in this region emphasize stringent welfare standards and harmonized oversight, which in turn shape vendor certification practices and study design expectations. Additionally, collaborative pan-regional consortia and public-private partnerships play a notable role in pooling resources for large-scale preclinical initiatives and in advancing standardized model validation criteria.

Asia-Pacific has emerged as a dynamic region for both service provision and model innovation, with rapid investment in gene editing capacity, breeding infrastructure, and contract research capabilities. Diverse regulatory approaches across countries create opportunities for regional specialization, while increasing local scientific expertise is fostering indigenous model development and translational research programs. Together, these regional patterns highlight the importance of tailoring sourcing strategies, compliance roadmaps, and partnership approaches to the specific risks and advantages present within each geography.

Strategic company behaviors and partnership models that drive competitive differentiation through specialization, data integration, and regulatory-aligned service offerings

Key company behaviors in the animal model ecosystem reflect strategic prioritization around specialization, vertical integration, and collaborative service delivery. Leading providers are investing in high-fidelity genetically engineered capabilities and robust breeding programs to offer differentiated model portfolios, while many service firms are expanding their analytics and bioinformatics layers to add value beyond animal production. This trend toward bundling technical services with deeper data interpretation aims to reduce translational gaps and to provide sponsors with more actionable insights from preclinical programs.

Another notable direction is the consolidation of capabilities through partnerships and alliances, enabling organizations to combine operational strengths-such as vivarium management, regenerative medicine expertise, or in vivo imaging-into comprehensive service offerings. At the same time, some providers are pursuing modular, outsourced arrangements that allow sponsors to access specific competencies without committing to full-scale integration. Across these strategies, investment in regulatory intelligence, quality management systems, and welfare accreditation is common, as customers increasingly demand demonstrable standards and traceability across the supply chain. These company-level choices influence competitive positioning, client retention, and the evolution of service-level expectations across the sector.

Practical and prioritized strategic recommendations for research leaders to enhance model fidelity, fortify supply chains, and elevate welfare compliance while accelerating translational outcomes

Industry leaders should adopt a proactive mix of scientific investment, supply chain resilience, and governance enhancements to capitalize on current opportunities and mitigate emerging risks. First, embedding advanced genetically engineered model capabilities-especially CRISPR-enabled platforms and comprehensive phenotyping workflows-will improve target validation and reduce downstream translational uncertainty. Complementing this, organizations should formalize model characterization standards and establish cross-functional review processes that ensure reproducibility and defendable scientific rationale.

Second, supply chain strategies must evolve to reduce exposure to trade policy shifts and supply interruptions. This involves diversifying vendor relationships, qualifying regional suppliers, and developing contingency inventories for mission-critical materials. In addition, investing in localized breeding capacity or regional partnerships can shorten lead times and provide operational buffers during periods of commerce volatility. Third, companies should elevate welfare and compliance governance by integrating enhanced monitoring technologies, independent audits, and staff competency programs that align with evolving ethical expectations and regulatory scrutiny.

Finally, leaders should leverage data science and digital platforms to achieve higher experimental efficiency. Standardizing metadata capture, adopting interoperable laboratory systems, and deploying machine learning for endpoint prediction will increase reproducibility and support faster decision cycles. Combined, these actions enhance scientific credibility, operational stability, and stakeholder trust, positioning organizations to sustain translational momentum while remaining responsive to policy and ethical imperatives.

Robust multi-source research methodology combining expert consultations, systematic literature synthesis, and iterative validation to ensure defensible and actionable insights

The research methodology underpinning this analysis leverages a layered approach that synthesizes primary qualitative insights with structured secondary validation. Primary inputs include consultations with subject-matter experts across preclinical research, veterinary sciences, and regulatory affairs to capture nuanced operational realities and emerging scientific trends. These interviews were supplemented by a systematic review of peer-reviewed literature, technical guidance documents, and recognized standards to contextualize technological advances and welfare practices.

Data triangulation ensured robustness by cross-referencing expert perspectives with publicly available technical reports and documented policy changes. Wherever applicable, methodological transparency was maintained through clear documentation of inclusion criteria, definitions for model classes, and the provenance of technical assertions. Ethical considerations guided the process throughout, with respect for data privacy and professional confidentiality in all expert engagements. This multi-source, iterative approach supports a defensible interpretation of sector dynamics and yields insights tailored to decision-makers requiring both operational guidance and scientific credibility.

A conclusive synthesis emphasizing the need to integrate scientific precision, ethical governance, and supply chain resilience to sustain translational success

In conclusion, the animal model landscape is entering a period of refined specialization, heightened ethical accountability, and operational recalibration. Scientific advances-especially in gene editing and phenotype characterization-are improving the translational precision of models, while at the same time regulators and stakeholders are raising the bar for welfare and reproducibility. These concurrent forces require organizations to be deliberate in model selection, to strengthen supply chain agility, and to invest in data and governance infrastructures that support reliable translational outcomes.

Looking forward, success will depend on the ability to integrate technological capabilities with responsible stewardship and pragmatic operational planning. Organizations that proactively align their scientific agendas with resilient procurement practices and transparent welfare governance will be better positioned to deliver high-quality preclinical evidence and to respond to policy or market shifts with agility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of CRISPR/Cas9 gene-edited animal models for rare disease research and drug discovery
  • 5.2. Growing preference for humanized mouse models in oncology immunotherapy efficacy and safety evaluation
  • 5.3. Integration of AI-powered image analysis and behavioral tracking in preclinical animal model phenotyping workflows
  • 5.4. Increasing investment in large animal models such as pigs and non-human primates for xenotransplantation studies
  • 5.5. Emergence of organ-on-a-chip and 3D bioprinted tissue platforms as alternatives to traditional animal testing
  • 5.6. Regulatory pressure driving development of in vitro and computational models to reduce reliance on animal experiments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Model Market, by Animal Type

  • 8.1. Nonrodents
    • 8.1.1. Dogs
    • 8.1.2. Nonhuman Primates
    • 8.1.3. Rabbits
  • 8.2. Rodents
    • 8.2.1. Hamsters & Guinea Pigs
    • 8.2.2. Mice
    • 8.2.3. Rats

9. Animal Model Market, by Model Type

  • 9.1. Disease Models
  • 9.2. Genetically Engineered Models
    • 9.2.1. CRISPR Models
    • 9.2.2. Knock-In Models
    • 9.2.3. Knockout Models
    • 9.2.4. Transgenic Models
  • 9.3. Pharmacological Models
  • 9.4. Surgical Models

10. Animal Model Market, by Application

  • 10.1. ADME & PK Studies
  • 10.2. Disease Research
  • 10.3. Drug Discovery & Development
  • 10.4. Toxicology Assessment

11. Animal Model Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals & Diagnostic Laboratories
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Animal Model Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Animal Model Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Animal Model Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Charles River Laboratories International, Inc.
    • 15.3.2. Envigo RMS, Inc.
    • 15.3.3. The Jackson Laboratory
    • 15.3.4. Taconic Biosciences, Inc.
    • 15.3.5. Laboratory Corporation of America Holdings
    • 15.3.6. Wuxi AppTec Co., Ltd.
    • 15.3.7. Evotec AG
    • 15.3.8. Crown Bioscience, Inc.
    • 15.3.9. Janvier Labs SAS
    • 15.3.10. GemPharmatech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL MODEL MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANIMAL MODEL MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL MODEL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANIMAL MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANIMAL MODEL MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANIMAL MODEL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANIMAL MODEL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANIMAL MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANIMAL MODEL MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL MODEL MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANIMAL MODEL MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANIMAL MODEL MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ANIMAL MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ANIMAL MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL ANIMAL MODEL MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL ANIMAL MODEL MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. GCC ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. GCC ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. GCC ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. GCC ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. GCC ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 316. GCC ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 317. GCC ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 318. GCC ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 319. GCC ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. GCC ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. GCC ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 322. GCC ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 323. GCC ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 324. GCC ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 325. GCC ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. GCC ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 340. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 343. BRICS ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 344. BRICS ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 345. BRICS ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. BRICS ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. BRICS ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 348. BRICS ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 349. BRICS ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 350. BRICS ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 351. BRICS ANIMAL MOD